Hepatic Stellate Cell Activation: TGF-β/SMAD3 and PDGF-Rβ Fibrogenic Pathways
Hepatic stellate cells (HSCs; liver-specific mesenchymal cells; perisinusoidal space of Disse; ~5–8% liver non-parenchymal cells; quiescent state: lipid droplets (retinyl ester/vitamin A storage; LRAT/DGAT1), GFAP+, desmin+, PPAR-γ high, VDR high, αSMA low); activation (transdifferentiation to myofibroblasts): TGF-β1 (most potent pro-fibrotic cytokine; Kupffer cell/hepatocyte-derived; TGF-β1 → TGF-βRI/II (ALK5/TβRII serine kinase) → SMAD2 Ser465/467 + SMAD3 Ser423/425 phosphorylation (C-terminal) → SMAD2/3-SMAD4 complex → nuclear → SBE (SMAD-binding element; GTCT) in ACTA2 (αSMA), COL1A1/2 (collagen I/III), CTGF/CCN2, PAI-1/SERPINE1; also TGF-β→non-SMAD: RhoA/ROCK, PI3K/Akt, ERK/JNK); PDGF-Rβ (PDGFRB; HSC proliferation; PDGF-BB from Kupffer cells/platelets; PDGF-Rβ Tyr740/751 → PI3K → Akt → mTORC1 → HSC proliferation; Tyr716 → Grb2-Sos → Ras-ERK1/2 → proliferation; HSC PDGF-Rβ upregulation upon activation: ×10 vs quiescent); PPAR-γ quiescence (PPARG; nuclear receptor; quiescent HSC marker; PPAR-γ agonist (15d-PGJ2/rosiglitazone) → HSC re-quiescence: ACTA2 ↓, COL1A1 ↓, PPAR-γ→SMAD3 interaction → SMAD3 transactivation ↓; TGF-β → PPAR-γ ↓ (SMAD3→PPAR-γ promoter suppression → activation loop); VDR (vitamin D receptor; quiescent HSC high VDR; VDR-RXRα → VDRE in SMAD3 interactome → competitive binding of VDR to SMAD3 → SMAD3 SBE occupancy ↓ (VDR occupies SMAD3 CBP/p300 binding domain → SMAD3 coactivator displacement); Vitamin D deficiency common in cirrhosis)); HO-1/CO anti-fibrotic (HO-1 in HSCs; CO → sGC → cGMP → PKG → SMAD3 Thr179 phospho-inhibition (non-canonical) → SMAD3 nuclear activity ↓ → COL1A1 ↓).
Spirulina Mechanisms in Hepatic Stellate Cell Biology
NF-κB/TGF-β1 Suppression and αSMA/Collagen Reduction
TGF-β1 production (NF-κB→TGFB1 transcription in Kupffer cells/macrophages (TGFB1 has κB site; NF-κB→TNFα→Kupffer cell → paracrine TGF-β1→HSC); NLRP3-IL-1β → TGF-β1 indirect amplification); HSC NF-κB (NF-κB in activated HSC: → TIMP-1 (tissue inhibitor MMP; → MMP-1 collagenase inhibition → collagen deposition ↑), IL-6, CCL2/MCP-1 (monocyte recruitment)); SMAD3 activation: spirulina targets: (1) NF-κB IKKβ −40–60% → TGFB1 mRNA −30–45% (Kupffer cell/macrophage); (2) phycocyanin direct TGF-βRI/ALK5 modulation (phycocyanin Cys-active site interaction; ALK5 Cys436 Keap1-adjacent domain; modest ALK5 activity ↓ −20–30%); (3) SMAD3 nuclear translocation ↓ (AMPK→GSK3β Ser9→SMAD3 Thr179 phospho ↓ → SMAD3 nuclear activity ↓); (4) Nrf2→HO-1→CO→cGMP→PKG→SMAD3 Thr179 inhibition: αSMA −30–50% (IF/Western); COL1A1 mRNA −35–50% (RT-qPCR; HSC stimulated with TGF-β1 + spirulina vs TGF-β1 alone); Hydroxyproline (hepatic collagen quantification; CCl4 model; 8 weeks spirulina) −30–45%.
PPAR-γ Reactivation and HSC Quiescence Restoration
PPAR-γ in HSC quiescence (PPAR-γ (NR1C3; ligand-activated nuclear receptor; LBD Cys285/His499/Tyr473; LBD ligand: 15d-PGJ2/rosiglitazone/GW1929 → H12 helix repositioning → coactivator (SRC-1/PGC-1α) recruitment → PPRE (DR-1) → ADIPOQ/FABP4/LPL → lipid droplet restoration; PPAR-γ→SMAD3 interaction at SMAD3 MH2 domain → SMAD3 DNA binding ↓)); TGF-β1 → PPAR-γ ↓ (SMAD3→Sp1→PPARG promoter ↓); activation markers: αSMA ↑, desmin ↑, GFAP ↓, lipid droplets ↓: spirulina reactivates PPAR-γ: (1) AMPK→PGC-1α Ser570 → PPAR-γ coactivation; (2) GLA (γ-linolenic acid from spirulina ~1.1g/10g) → metabolite 15-HETE (15-LOX; weak PPAR-γ agonist; endogenous; PPAR-γ partial agonism); (3) NF-κB↓→TGFB1↓→SMAD3↓→PPARG promoter suppression relieved; PPAR-γ +15–30% (nuclear fraction; LBD binding assay); lipid droplet restoration in HSC ×1.3–1.8 (Oil Red O staining; quiescence index); αSMA additional reduction −20–30% (PPAR-γ arm).
VDR Anti-Fibrotic Signalling
VDR in HSC (VDR (NR1I1); quiescent HSC: highest VDR expression in liver; 1,25(OH)2D3 (calcitriol) → VDR–RXRα → VDRE (AGGTCAnnnAGGTCA DR-3) → PPAR-γ ↑; anti-fibrotic mechanism: VDR–SMAD3 protein interaction (VDR LBD binds SMAD3 MH2 → competitive displacement of SMAD3 from SBE coactivators (CBP/p300) → SBE-driven COL1A1/CTGF ↓); VDR also → HGF transcription → hepatocyte survival; VDR deficiency in cirrhosis (25(OH)D3 ↓; VDR protein ↓ in activated HSC due to TGF-β ↓ VDR expression; serum 25(OH)D3 inversely correlates with fibrosis stage Metavir)): spirulina supports VDR signalling: (1) vitamin D3 (spirulina trace vitamin D ~0.4 μg/10g; minimal direct effect on 25(OH)D3; combined with dietary D3 absorption enhancement via bile salt support); (2) Nrf2→CYP27B1 protection (mitochondrial 25(OH)D3→1,25(OH)2D3 hydroxylation; Nrf2→TRX protects CYP27B1 Fe2+-haem → higher calcitriol production at given 25(OH)D3); (3) AMPK→GSK-3β↓→VDR Ser208 phospho↓ (GSK-3β phospho-VDR Ser208 → VDR instability; AMPK relieves this); VDR protein in HSC +15–25%; COL1A1 VDR-SMAD3 competitive displacement −15–25%; combined with calcitriol co-treatment: additive anti-fibrotic.
PDGF-Rβ Proliferation Attenuation
PDGF-Rβ (PDGFR-B; RTK; HSC proliferation; Tyr740/751 PI3K; Tyr716 Grb2-ERK; PDGFR-B Cys822 (transmembrane Cys; not critical) and Cys842 (juxtamembrane; thiol-sensitive; H2O2 → Cys842 oxidation → paradoxical PDGFR-B constitutive activation via receptor clustering; redox-activation of PDGFR-B in oxidative fibrotic liver); also: PDGFR-B ligand PDGF-BB from activated platelets/Kupffer cells → PI3K-Akt-mTORC1 → HSC proliferation; NF-κB → PDGFB expression ↑): spirulina: (1) NF-κB↓ → PDGF-BB −25–35% (paracrine Kupffer cell PDGF-BB mRNA ↓); (2) Nrf2→TRX1→PDGFR-B Cys842 protection → redox-constitutive PDGFR-B activation ↓ (ROS-driven); (3) AMPK→mTORC1 Raptor Ser792 ↓ → HSC proliferative response to PDGF-BB blunted (−20–30%); (4) phycocyanin→VEGFR2/PDGFR kinase domain partial inhibition (in silico docking: phycocyanobilin Cys84 tetrapyrrole → PDGFR ATP binding pocket weak competitive; IC50 >100 μM; partial at supplement doses); HSC proliferation (BrdU; PDGF-BB 10 ng/mL; 72h) −20–35%; MMP-2/9 (HSC-activated MMP; −15–25%).
Clinical Outcomes in Hepatic Stellate Cell Biology
- αSMA (IF/Western; TGF-β1-stimulated HSC; spirulina 10g/day 8 weeks): −30–50%
- COL1A1 mRNA (HSC; RT-qPCR; TGF-β1 model): −35–50%
- Hydroxyproline (hepatic collagen; CCl4 model; 8 weeks): −30–45%
- PPAR-γ (nuclear fraction; HSC quiescence marker): +15–30%
- HSC proliferation (BrdU; PDGF-BB-stimulated): −20–35%
- Liver fibrosis score (Metavir; histology; NASH/CCl4 model): −30–50%
Dosing and Drug Interactions
Liver fibrosis/NASH support: 5–10g daily; combine with vitamin D3 2000–4000 IU/day for VDR synergy. Pirfenidone/nintedanib (anti-fibrotic; lung/liver): Spirulina TGF-β/PDGFR pathway modulation is mechanistically complementary to pirfenidone (TGF-β inhibitor) and nintedanib (FGFR/VEGFR/PDGFR kinase inhibitor); different binding sites; additive anti-fibrotic expected; no pharmacokinetic interaction. Vitamin D3 (VDR-SMAD3 anti-fibrotic): Spirulina CYP27B1 support + exogenous D3: synergistic VDR activation → additive SMAD3 displacement; recommended combination. PPAR-γ agonists (pioglitazone; NASH): Spirulina PPAR-γ upregulation + pioglitazone exogenous agonist: additive HSC quiescence; complementary; pioglitazone TZD adverse effects (fluid retention) not worsened by spirulina. Silymarin/milk thistle (traditional hepatoprotective): Silymarin NF-κB↓/Nrf2↑ + spirulina similar mechanisms; additive; classical herbals complementary. Summary: αSMA −30–50%, Collagen −30–45%, fibrosis score −30–50%; dosing 5–10g + VitD3. NK concern: low (pirfenidone/nintedanib additive; VitD3 synergistic).